Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,601–4,700 of 15,747
Zhang, Y., Li, D., Shen, Y., Li, S., Lu, S., & Zheng, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161507 · Cited by 29
“BNT162b21 (42) and mRNA-1273 (43) are two currently approved anti-coronavirus disease 2019 (COVID19) vaccines that use LNPs to deliver antigenic mRNA.”
BackgroundShehab, M., Alrashed, F., Alfadhli, A., Alotaibi, K., Alsahli, A., Mohammad, H., Cherian, P., Al‐Khairi, I., Thanaraj, T. A., Channanath, A. M., et al. (2021) · Vaccines · doi:10.3390/vaccines9121471 · Cited by 22
Stewart, E. L., Counoupas, C., Johansen, M. D., Nguyen, D. H., Miemczyk, S., Hansbro, N. G., Ferrell, K. C., Ashhurst, A. S., Alca, S., Ashley, C. L., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00578-9 · Cited by 26
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
Qiao, Y., Wotring, J. W., Zhang, C. J., Jiang, X., Xiao, L., Watt, A., Gattis, D., Scandalis, E., Freier, S. M., Zheng, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281281 · Cited by 21
What should define a SARS-CoV-2 “breakthrough” infection?
Schieffelin, J. S., Norton, E. B., & Kolls, J. K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151186 · Cited by 22
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
(2021) · doi:10.1101/2021.09.29.21264199 · Cited by 230
COVID-19 Vaccines in Patients With Chronic Liver Disease
Sharma, A., Patnaik, I., Kumar, A. S., & Gupta, R. K. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.013 · Cited by 21
“Systemic symptoms like fever, joint pains and chills occurred more commonly in the young patients and were more common after the second dose.(7) The above trial included 214 patients withmild liver disease and only three patients with moderate or severe liver disease.”
BackgroundSonoda, J., Mizoguchi, I., Inoué, S., Watanabe, A., Sekine, A., Yamagishi, M., Miyakawa, S., Yamaguchi, N., Horio, E., Katahira, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109094 · Cited by 24
“The current worldwide success of vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), BNT162b2 [1] and mRNA-1273 [2] has attracted great interest in the prophylactic effectiveness and safety of mRNA vaccines by intramuscular injection using a needled syringe [3].”
BackgroundAbutaleb, M., Makeen, H. A., Meraya, A. M., Alqahtani, S. S., Al-Mass, B. I., Aljazaeri, R. O., Alhazmi, B. D., Kalakattawi, A. M. N., & Alajam, A. A. (2023) · Vaccines · doi:10.3390/vaccines11010112 · Cited by 21
Dietze, P., Hall, C., Price, O. H., Stewart, A. C., Crawford, S., Peacock, A., & Maher, L. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13399 · Cited by 24
“At the time, a second wave of COVID-19 cases was subsiding in Victoria (peak daily new cases of 111 on 28 March and 725 on 5 August 2020, respectively), stringent social mobility restrictions were being eased, and initial results from Phase III trials of a number of candidate vaccines were released [10].”
BackgroundWussow, F., Kha, M., Kim, T. H., Ly, M., Yll, M., Kar, S., Lewis, M. G., Chiuppesi, F., & Diamond, D. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00640-y · Cited by 23
Sala, L. L., Gandini, S., Bruno, A., Allevi, R., Gallazzi, M., Senesi, P., Palano, M. T., Meregalli, P., Longhi, E., Sommese, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.798813 · Cited by 23
“The recent clinical trial demonstrated the efficacy of Comirnaty starting at 28 days in producing antibodies against SARS (7).”
BackgroundAppel, K. S., Geisler, R., Maier, D., Miljukov, O., Pütz, S. M., & Vehreschild, J. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad618 · Cited by 21
“Only one score asked for the vaccination status [36], as most scores were developed on data from the early pandemic. vaccination status may be among the most critical outcome predictors today [37, 38].”
BackgroundGori, D., Reno, C., Remondini, D., Durazzi, F., & Fantini, M. P. (2021) · Vaccines · doi:10.3390/vaccines9020173 · Cited by 22
Abrams, E. M., Greenhawt, M., Alqurashi, W., Singer, A. G., & Shaker, M. S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.05.038 · Cited by 24
Ferner, R. E., Stevens, R., Anton, C., & Aronson, J. K. (2022) · Drug Safety · doi:10.1007/s40264-021-01138-z · Cited by 21
“One non-COVID-19 death occurred in the vaccine group and three in the control group; none was considered related to the vaccine.”
BackgroundInfluentialManiscalco, G. T., Manzo, V., Ferrara, A. L., Perrella, A., Battista, M. E. D., Salvatore, S., Graziano, D., Viola, A., Amato, G., Moreggia, O., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103455 · Cited by 21
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
Kulkarni, R., Chen, W.-C., Lee, Y., Kao, C., Hu, S.-L., Ma, H., Jan, J., Liao, C., Liang, J., Ko, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257191 · Cited by 21
Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy
Marschall, A. L. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00500-y · Cited by 22
Bostancı, Ö., Karaduman, E., Çolak, Y., Yılmaz, A. K., Kabadayı, M., & Bilgiç, S. (2022) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2022.103983 · Cited by 23
“Although it has been nearly two years since the World Health Organization (WHO) declared the first case with COVID-19 and effective vaccines have been developed (Polack et al., 2020), there are still incidences with severe disease and public events are still prohibited in many countries in order to contain the spread.”
A Case Report of Capsular Contracture Immediately Following COVID-19 Vaccination
Restifo, R. J. (2021) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojab021 · Cited by 21
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
Zhang, R., Leung, K., Liu, D., Fan, Y., Lu, L., Chan, P.-C., To, K. K., Chen, H., Yuen, K., Chan, K., et al. (2022) · mSphere · doi:10.1128/msphere.00915-21 · Cited by 22
“The incidence of serious adverse events (AEs) in both vaccines was low, and the most common systemic and local symptoms were tiredness and injection site pain, respectively (4, 7).”
BackgroundImpact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year
Ramirez, G. A., Argolini, L. M., Bellocchi, C., Moroni, L., Della‐Torre, E., Farina, N., Caporali, R. F., Beretta, L., Gerosa, M., Bozzolo, E. P., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108845 · Cited by 22
Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination
Yasuda, E., Matsumiya, W., Maeda, Y., Kusuhara, S., Nguyen, Q. D., Nakamura, M., & Hara, R. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101532 · Cited by 21
Álvarez-Díaz, D. A., Muñoz, A. L., Tavera-Rodríguez, P., Herrera-Sepúlveda, M. T., Ruiz-Moreno, H. A., Laiton‐Donato, K., Franco-Muñoz, C., Peláez‐Carvajal, D., Cuellar, D., Muñoz-Suarez, A. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10020180 · Cited by 22
“Finally, this study shows the importance of continuing the surveillance programs of emerging variants, as well as the need to evaluate the resistance of VOCs and VOIs to humoral immunity elicited by the vaccines.”
BackgroundThe clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 30
Knowledge, acceptance, and hesitancy of COVID-19 vaccine among health care workers in Nigeria
Robinson, E. D., Wilson, P., Eleki, B. J., & Wonodi, W. (2021) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_4_21 · Cited by 27
Extracellular Vesicles as Delivery Systems in Disease Therapy
Picon, M. A., Wang, L., Ferreira, A. D. F., Dong, C., & Marzouka, G. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417134 · Cited by 24
Charilaou, P., Tricarico, C. J., Battat, R. J., Scherl, E., Longman, R., & Lukin, D. J. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.007 · Cited by 21
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Fukushi, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37128-1 · Cited by 27
Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
Bartley, J. M., Cadar, A. N., & Martin, D. E. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1909617 · Cited by 23
“Reports submitted to the FDA and publications showed that the Pfizer-BioNTech BNT162b2 vaccine had 94.6% vaccine efficacy for at least 7 days after the second dose among the 36,523 participants (Polack et al. 2020).”
BackgroundInfluentialPetráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02663-z · Cited by 25
“Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar.”
InfluentialSingle intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Zhang, K., Tao, H., Zhu, D., Yue, Z., Hu, S., Wu, Y., Yan, N., Hu, Y., Liu, S., Liu, M., et al. (2026) · Science · doi:10.1126/science.adu9394 · Cited by 34
COVID‐19 vaccine in patients with Dravet syndrome: Observations and real‐world experiences
Hood, V. L., Berg, A. T., Knupp, K. G., Koh, S., Laux, L., Meskis, M. A., Ali, Q. Z., Perry, M. S., Scheffer, I. E., Sullivan, J. E., et al. (2022) · Epilepsia · doi:10.1111/epi.17250 · Cited by 20
Kato, H., Miyakawa, K., Ohtake, N., Go, H., Yamaoka, Y., Yajima, S., Shimada, T., Goto, A., Nakajima, H., & Ryo, A. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.11.021 · Cited by 23
“274 and reducing disease severity range from 94% to 95% [4,5].”
BackgroundEfficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
(2021) · doi:10.1101/2021.05.13.21256639 · Cited by 1,085
“By the beginning of 2021, several vaccine candidates have emerged as safe and effective in preventing Covid-19, supporting their emergency use around the world.(3-6) Recent reports from the United Kingdom (UK), Brazil, and South Africa in late 2020 have confirmed the emergence of SARS-CoV2 variants (B.”
BackgroundResultEffects of Covid-19 vaccination on different semen parameters
Abd, Z. H., Muter, S. A., Saeed, R. A. M., & Ammar, O. F. (2022) · Basic and Clinical Andrology · doi:10.1186/s12610-022-00163-x · Cited by 23
“The disease affected various aspects of life, including but not limited to social, economic and health aspects [4].”
BackgroundPEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines
Xiao, W., Wang, F., Gu, Y., He, X., Fan, N., Zheng, Q., Qin, S., He, Z., Wei, Y., & Song, X. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108755 · Cited by 23
Lim, S. M., Chan, H. C., Santosa, A., et al. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2021160 · Cited by 21
Challenges and opportunities in the development of mucosal mRNA vaccines
Kirtane, A. R., Tang, C., Freitas, D., Bernstock, J. D., & Traverso, G. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102388 · Cited by 27
Arora, P., Kempf, A. M., Nehlmeier, I., Sidarovich, A., Krüger, N., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S. R., Jäck, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449568 · Cited by 20
Ferreiro‐Iglesias, R., Piqueras, M., Ricart, E., Sempere, L., Roca, M., de Carpi, J. M., Benítez, O., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.03.012 · Cited by 23
Dheir, H., Toçoğlu, A. G., Toptan, H., Pınar, M., Demirci, T., Köroğlu, M., Yaylacı, S., Genç, A. B., Genç, A. C., Fırat, N., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27714 · Cited by 20
“The response of antibodies after various COVID‐19 vaccines have been shown in almost all normal populations, whereas contradictory results have been detected in different kidney diseases.(3,21) The antibody response of mRNA‐based COVID‐19 TABLE 1 Comparison of baseline clinical features and laboratory results”
BackgroundResultvan Asbeck, A. H., Dieker, J. W. C., Egberink, R. O., van den Berg, L., van der Vlag, J., & Brock, R. E. (2021) · Biomedicines · doi:10.3390/biomedicines9050511 · Cited by 21
“The delivery of messenger RNA as a therapeutic modality has just had its breakthrough in the clinical approval of two SARS-CoV2 vaccines [1,2].”
Corneal Graft Rejection After Inactivated SARS-CoV-2 Vaccine: Case Report
Simão, M. F., & Kwitko, S. (2021) · Cornea · doi:10.1097/ico.0000000000002970 · Cited by 21
Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy
Cao, H., Wang, Y., Luan, N., Lin, K., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9121440 · Cited by 25
“Ionizable lipid nanoparticle (LNP)-encapsulated mRNA vaccines have been approved by the FDA within one year of their development to prevent coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) [1,2].”
BackgroundVerstegen, N. J. M., Hagen, R. R., van den Dijssel, J., Kuijper, L. H., Kreher, C., Ashhurst, T. M., Kummer, L. Y. L., Steenhuis, M., Duurland, M. C., de Jongh, R., et al. (2022) · eLife · doi:10.7554/elife.77969 · Cited by 21
“, 2021) and are highly efficacious (>94%) in reducing transmissibility and induction of serious disease and hospitalization of most variants (Baden et al., 2021; Lyngse et al., 2021; Polack et al., 2020; Tenforde and Patel, 2021).”
BackgroundStrategies for the Management of Spike Protein-Related Pathology
Halma, M. T. J., Plothe, C., Marik, P. E., & Lawrie, T. A. (2023) · Microorganisms · doi:10.3390/microorganisms11051308 · Cited by 23
“These are related to Pfizer’s BNT162b2 [158], Moderna’s mRNA-1273 [159], Johnson & Johnson’s Ad26.”
Bardenheier, B. H., Gravenstein, S., Blackman, C., Gutman, R., Sarkar, I. N., Feifer, R. A., White, E. M., McConeghy, K. W., Nanda, A., Bosco, E., et al. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.024 · Cited by 21
Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 CasesPreprint
Villela, D. A. M., de Noronha, T. G., Bastos, L. S., Pacheco, A. G., Cruz, O. G., Carvalho, L. M., Codeço, C. T., Gomes, M. F. D. C., Coelho, F. C., Freitas, L. P., et al. (2021) · medRxiv · doi:10.1101/2021.09.10.21263084 · Cited by 30
Gómez, C. E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., Sorzano, C. Ó. S., Sánchez-Corzo, C., Plana, M., García, F., et al. (2021) · Vaccines · doi:10.3390/vaccines9090959 · Cited by 21
“Phase III clinical trials with both vaccines have shown efficacies above 90% against SARS-CoV-2 infection, and currently hundreds of millions of people are being vaccinated with these mRNA vaccines [7,8].”
BackgroundChallenges and Issues of Anti-SARS-CoV-2 Vaccines
Blumental, S., & Debré, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.664179 · Cited by 24
“6), as assessed 7 days after the second dose (28) and recent data under review are reassuring about the protection conferred against two new variants (29).”
BackgroundRisk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections
Suleyman, G., Fadel, R. A., Brar, I., Kassab, R., Khansa, R., Sturla, N., Alsaadi, A., Latack, K. A., Miller, J. B., Tibbetts, R. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac116 · Cited by 26
“Randomized clinical trials have demonstrated high vaccine efficacies (>94%) for the mRNA-based vaccines against COVID-19 [1, 2].”
Güven, D. C., Şahin, T. K., Akın, S., & Uckun, F. M. (2022) · The Oncologist · doi:10.1093/oncolo/oyac032 · Cited by 24
The need for a global COVID-19 maternal immunisation research plan
Bardají, A., Sevene, E., Cutland, C., Menéndez, C., Omer, S. B., Aguado, T., & Muñoz, F. M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00146-x · Cited by 20
Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
Yamakawa, M., Nakahara, K., Nakanishi, T., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8851-21 · Cited by 20
“Whereas, adverse events were more commonly reported among the mRNA COVID-19 vaccination group (13).”
BackgroundBorah, P., Xiao, X., & Lee, D. K. L. (2022) · American Journal of Health Promotion · doi:10.1177/08901171221075019 · Cited by 25
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study
Ostropolets, A., & Hripcsak, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061126 · Cited by 19
Kocatürk, E., Salameh, P., Saraç, E., Vera, C., Thomsen, S. F., Zuberbier, T., Ensina, L. F., Popov, T. A., van Doorn, M. B. A., Giménez‐Arnau, A. M., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.019 · Cited by 25
The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data
Li, Z., Liu, X., Liu, M., Wu, Z., Liu, Y., Li, W., Liu, M., Wang, X., Gao, B., Luo, Y., et al. (2021) · Vaccines · doi:10.3390/vaccines9111328 · Cited by 21
“Considering that the vaccine becomes effective 3–4 weeks after injection [16], we chose a maximum lag period of 30 days.”
BackgroundCOVID-19 vaccine associated axillary lymphadenopathy – A systematic review
Co, M., Wong, P.-M., & Kwong, A. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100546 · Cited by 22
Chen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Söderdahl, G., Österborg, A., Smith, C. I. E., Vesterbacka, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104700 · Cited by 19
Loconsole, D., Sallustio, A., Accogli, M., Leaci, A., Sanguedolce, A., Parisi, A., & Chironna, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.007 · Cited by 22
“Clinical trial data demonstrate that two doses of the BNT162b2 vaccine confer 95% protection against COVID-19 caused by wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2].”
Droplet Microfluidics for High-Resolution Virology
Jing, W., & Han, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00615 · Cited by 22
Li, X., Pan, Y., Yin, Q., Wang, Z., Shan, S., Zhang, L., Yu, J., Qu, Y., Sun, L., Gui, F., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00449-4 · Cited by 20
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 23
Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures
Kruse, M., Altattan, B., Laux, E., Grasse, N., Heinig, L., Möser, C., Smith, D. M., & Hölzel, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-16914-9 · Cited by 21
(2021) · doi:10.1101/2021.12.09.21267516 · Cited by 414
“[9] Polack FP, Thomas SJ, Kitchin N, et al.”
BackgroundCillo, A. R., Somasundaram, A., Shan, F., Cardello, C., Workman, C. J., Kitsios, G. D., Ruffin, A. T., Kunning, S. R., Lampenfeld, C., Onkar, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100476 · Cited by 32
Briciu, V. T., Topan, A. V., Calin, M., Dobrota, R., Leucuta, D., & Lupșe, M. S. (2023) · Healthcare · doi:10.3390/healthcare11030373 · Cited by 20
Xiao, C., Mao, L., Wang, Z., Gao, L., Zhu, G., Su, J., Chen, X., Yuan, J., Hu, Y., Yin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103934 · Cited by 23
mRNA COVID‐19 vaccine and oral lichen planus: A case report
Caggiano, M., Amato, M., Spirito, F. D., Galdi, M., & Sisalli, L. (2022) · Oral Diseases · doi:10.1111/odi.14184 · Cited by 23
“BNT162b2 (Comirnaty) is a vaccine against COVID-19, based on messenger RiboNucleic Acid (m-RNA) technology, capable of encoding for SARS-CoV 2 spike protein, which is responsible of viral binding to target human cells (Polack et al., 2020).”
BackgroundInfluentialPanikkar, A., Lineburg, K. E., Raju, J., Chew, K. Y., Ambalathingal, G. R., Rehan, S., Swaminathan, S., Crooks, P., Texier, L. L., Beagley, L., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010339 · Cited by 21
“Ongoing vaccination programs will have a profound impact upon the incidence of COVID19 in the next few years [14,15].”
BackgroundAutoimmune liver diseases and SARS-CoV-2
Sgamato, C., Rocco, A., Compare, D., Minieri, S., Marchitto, S. A., Maurea, S., & Nardone, G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1838 · Cited by 26
Almas, T., Rehman, S., Mansour, E. Z., Khedro, T., Alansari, A., Malik, J., Alshareef, N., Nagarajan, V. R., Al-Awaid, A. H., Alsufyani, R., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112843 · Cited by 24
Non‐Viral Gene Delivery Systems: Current Advances and Therapeutic Applications
Wang, F., Liang, L., Wang, C., Zhang, C., Ye, Y., Dou, L., Shi, L., Zhou, D., & Sun, X. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500684 · Cited by 26
Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis
Danladi, J., & Sabir, H. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577632 · Cited by 27
“…Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273) are mRNA vaccines, reporting a success of 90–95% efficacy against COVID-19 (Baden et al., 2021; Polack et al., 2020), while the AdV vaccines (ChAdOx1 nCoV-19) and Gam-COVID-vac (Sputnik V) have an average efficacy of 70% and 91% protection…”
BackgroundSide effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study
Kadali, R. A. K., Janagama, R., Yedlapati, S. H., Kanike, N., Gajula, V., Madathala, R. R., Poddar, S., Sukka, N., Jogu, H. R., Racherla, S., et al. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2021.10.017 · Cited by 20
“Data from the recent studies with detailed review of systems among mRNA COVID-19 vaccine recipients suggests that they would experience wide range of non-life threatening local and systemic post-vaccination symptoms but still has greater acceptance to these vaccines.(4,5,7-9) Clinical trials have generally excluded pa…”
InfluentialLi, J., Hu, J., Jin, D., Huo, H., Chen, N., Lin, J., & Lu, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02919-1 · Cited by 25
“Previous studies have shown that combining ILs bearing long alkyl chains with cKK-E12 exhibits synergistic effects to enhance mRNA delivery [21].”
BackgroundNanoscience versus Viruses: The SARS‐CoV‐2 Case
Gościańska, J., Freund, R., & Wuttke, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107826 · Cited by 21
Brockman, M., Mwimanzi, F., Lapointe, H., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L.-Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.06.21263149 · Cited by 3
Bieniasz, P. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab070 · Cited by 22
Funakoshi, Y., Yakushijin, K., Ohji, G., Hojo, W., Sakai, H., Takai, R., Nose, T., Ohata, S., Nagatani, Y., Koyama, T., et al. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.021 · Cited by 21
“Further, in a phase 3 trial of BNT162b2, vaccine efficacy appeared to be lower in the Asian population than in the total population [6].”
InfluentialTechnologies Enabling Single-Molecule Super-Resolution Imaging of mRNA
Tingey, M., Schnell, S. J., Yu, W., Saredy, J., Junod, S. L., Patel, D., Alkurdi, A., & Yang, W. (2022) · Cells · doi:10.3390/cells11193079 · Cited by 21
“RNA vaccines against SARS-CoV-2 have exhibited high prophylactic efficiency against the disease during the two years since their development [12,13].”
BackgroundYaseen, A. R., Suleman, M., Qadri, A. S., Ali, A., Arshad, I., & Khan, D. M. (2023) · In Silico Pharmacology · doi:10.1007/s40203-023-00156-2 · Cited by 22
Vaccination for Respiratory Infections in Patients with Heart Failure
Girerd, N., Chapet, N., Roubille, C., Roncalli, J. G., Salvat, M., Mouquet, F., Lamblin, N., Gueffet, J.-P., Damy, T., Galinier, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194311 · Cited by 22
“The rates of serious adverse events and cardiovascular complications were comparable in the mRNA COVID‐19 vaccine and placebo groups [45,46].”
BackgroundRNA delivery with a human virus-like particle
Gutkin, A., Rosenblum, D., & Peer, D. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01124-x · Cited by 23
Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Sakai, H., Hojo, W., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10020158 · Cited by 19
“Hematological disease status was stable in all patients, and none had developed COVID-19 prior to the first dose.”
BackgroundInfluentialCOVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports
Chen, J.-H., Ikwuanusi, I., Bommu, V. J. L., Patel, V., Aujla, H., Kaushik, V., & Cheriyath, P. (2022) · Cureus · doi:10.7759/cureus.21740 · Cited by 22
“To contain the pandemic, which has had severe medical, economic, and social implications, safe and efficient prophylactic vaccinations were urgently needed [18].”
BackgroundJafarzadeh, A., Jafarzadeh, S., Pardehshenas, M., et al. (2022) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13978 · Cited by 20
Short, K. K., Lathrop, S. K., Davison, C. J., Partlow, H. A., Kaiser, J. A., Tee, R. D., Lorentz, E. B., Evans, J. T., & Burkhart, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071455 · Cited by 25
“These vaccines cause adaptive immunity to the in situ production of the SARS-CoV-2 S (spike) protein, which has resulted in greater than 90% prevention of COVID-19 after SARS-CoV-2 infection in phase III trials [6,7].”
BackgroundLécuyer, D., Nardacci, R., Tannous, D., Gutierrez-Mateyron, E., Nathan, A. D., Subra, F., Primio, C. D., Quaranta, P., Petit, V., Richetta, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270081 · Cited by 22
“Sequences of indicated siRNAs are following: siGenome smart pool siRNAs against CASP-1 (siCASP-1, #M-004401-03-0010): (1) 5’-GACUCAUUGAACAUAUGCA-3’, (2) 5’AGACAUCCCACAAUGGGCU-3’, (3) 5’-GAAUAUGCCUGUUCCUGUG-3’, (4) 5’CCGCAAGGUUCGAUUUUCA-3’, siGenome smart pool non-targeting siRNAs (siCo.”
BackgroundInfluentialRaethke, M., van Hunsel, F. P. A. M., Luxi, N., Lieber, T., Bellitto, C., Mulder, E., Ciccimarra, F., Riefolo, F., Thurin, N. H., Roy, D., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.03.001 · Cited by 23
Girl, P., Zwirglmaier, K., von Buttlar, H., Wölfel, R., & Müller, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820151 · Cited by 20
Advances of nanomaterials‐based strategies for fighting against COVID‐19
Zeng, C., Hou, X., Bohmer, M., & Dong, Y. (2021) · View · doi:10.1002/viw.20200180 · Cited by 21
Distinct SARS-CoV-2 Antibody Responses Elicited by Natural Infection and mRNA Vaccination
de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Kahn, S., Palma, A. M., Parker, D. M., Chau, A. H., Leung, A., Grabar, C., et al. (2021) · eScholarship (California Digital Library) · Cited by 20
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents
Klein, N. P., Demarco, M., Fleming-Dutra, K. E., Stockwell, M. S., Kharbanda, A. B., Gaglani, M., Rao, S., Lewis, N., Irving, S. A., Hartmann, E., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2022-060894 · Cited by 20
Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
Matsumura, T., Takano, T., & Takahashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac064 · Cited by 24
Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 22
“Amongst the first COVID-19 vaccines to receive emergency use authorisation are messenger RNA (mRNA) vaccines, which demonstrated ~95% efficacy against symptomatic COVID19 in clinical trials [2,3].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.